Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Provided By GlobeNewswire
Last update: May 12, 2025
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG)
Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE’26
Read more at globenewswire.com
